Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
NK cell group:NK cells were injected by intravenous drip once a day for 2 to 3 times in total, each dose was 4 10^7 pieces /kg body weight,100ml normal saline suspension
Control group:100ml normal saline intravenous drip
Sponsors
Huzhou Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years old; 2. diagnosed with viral pneumonia such as new coronavirus; 3. voluntary informed consent
Exclusion criteria
Exclusion criteria: 1) left heart failure pulmonary edema; 2) pregnancy and lactation or perinatal period; 3) liver failure MELD score >40; 4) a history of deep vein thrombosis or pulmonary embolism in the past 3 months; 5) cases that the researcher judged to be unsuitable for the group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Monitoring of adverse events within 24 hours after infusion (including infusion related events and severe adverse reactions associated with non-primary disease); | — |
Secondary
| Measure | Time frame |
|---|---|
| Recovery time;Virus nucleic acid negative time and rate;The rate and time of main symptoms (fever, fatigue and cough) disappear;Pulmonary imaging changes;Arterial oxygen partial pressure and oxygenation index were measured 2 days after infusion;Blood RT;Serum inflammatory factors il-6, il-8, sp-d, pai-1, sicam-1, TNFa, CD4, CD8, CD54, CD69; | — |
Countries
China
Contacts
Public ContactEnhai Cui
Huzhou Central Hospital
Outcome results
None listed